Category Specific RSS

Categories: News

Top cosmetic dermatologist endorses Zelira’s cannabis-based acne treatment

In 1964 Israeli chemist Raphael Mcechoulam boarded a bus to the Weitzman Institute in Rehovot with 5 kilos of hashish he received from the Israeli police. He used the material to isolate and identify THC, the psychoactive compound in cannabis. The discovery saw him crowned as “the father of cannabis research”. 

Cannabinoid medicine specialist company Zelira Therapeutics (ASX: ZLD) is paying homage to the scientist by naming their new line of skincare products RAF FIVE. 

The Company has just launched the product line in the US through its dermatology subsidiary Ilera Derm. 

The line uses pharmaceutical-grade CBD in five products including a cleanser, acne spot treatment, moisturiser and SPF and acne treatments. The line will be Zelira’s first foray into the acne medication market worth over USD $11 billion worldwide. 

Alongside acne fighting and skin loving ingredients the products also contain Zylorma, a patent-pending acne treatment developed by Zelira in partnership with cosmetic dermatologist Dr. Karyn Grossman. Zylorma contains a mix of CBD, salicylic acid and other compounds to clear bacteria and unclog pores. 

Following a month of use, 45 people reported significant improvements in their skin including the improvement of blemishes, smoother, more even-toned skin and reduced incidence of blemishes. Results were noticeable after just 7 days’ use. 

CEO and Managing Director of Zelira, Dr. Oludare Odumosu said: “I am excited to announce the launch of Zelira’s Dermatology subsidiary and the RAF FIVE acne treatment line of skincare products. Dr. Grossman’s reputation and experience in the cosmetic dermatology industry, combined with Zelira’s peerless position in a cannabinoid space, is the perfect combination. We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the USD$11 billion acne treatment market where there is a high level of dissatisfaction with the existing products and unmet needs. Zelira is staking a claim in the cannabinoid- based, over- the counter skin care product market with our differentiated dermatology. 

Ilera Derm is working to develop more topical products which are anticipated to be launched next year. 

Samantha Freidin

Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.

Recent Posts

SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition

Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…

2 days ago

Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards

A major Australian research initiative is set to push forward global understanding of brain injury,…

2 weeks ago

Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion

Following a successful FY25 which saw a boost in gross profit after launching its refurbished…

3 weeks ago

Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program

Pivotal Metals (ASX:PVT) has locked in $5.4 million in fresh funding to accelerate exploration across…

3 weeks ago

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

1 month ago

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

1 month ago